- call +1-201-465-4211
- email sales@mrinsights.biz
Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
Scope of the Report:
This report studies the Gene Therapy for Age-related Macular Degeneration market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gene Therapy for Age-related Macular Degeneration market by product type and applications/end industries.
It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.
The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).
According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
The global Gene Therapy for Age-related Macular Degeneration market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gene Therapy for Age-related Macular Degeneration.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
RetroSense Therapeutics
REGENXBIO
AGTC
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Subretinal
Intravitreal
Unspecified
Market Segment by Applications, can be divided into
Monotherapy
Combination Therapy
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Gene Therapy for Age-related Macular Degeneration Market Overview
1.1 Product Overview and Scope of Gene Therapy for Age-related Macular Degeneration
1.2 Classification of Gene Therapy for Age-related Macular Degeneration by Types
1.2.1 Global Gene Therapy for Age-related Macular Degeneration Revenue Comparison by Types (2017-2023)
1.2.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Types in 2017
1.2.3 Subretinal
1.2.4 Intravitreal
1.2.5 Unspecified
1.3 Global Gene Therapy for Age-related Macular Degeneration Market by Application
1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Monotherapy
1.3.3 Combination Therapy
1.4 Global Gene Therapy for Age-related Macular Degeneration Market by Regions
1.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gene Therapy for Age-related Macular Degeneration Status and Prospect (2013-2023)
1.5 Global Market Size of Gene Therapy for Age-related Macular Degeneration (2013-2023)
2 Manufacturers Profiles
2.1 RetroSense Therapeutics
2.1.1 Business Overview
2.1.2 Gene Therapy for Age-related Macular Degeneration Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)
2.2 REGENXBIO
2.2.1 Business Overview
2.2.2 Gene Therapy for Age-related Macular Degeneration Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)
2.3 AGTC
2.3.1 Business Overview
2.3.2 Gene Therapy for Age-related Macular Degeneration Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Revenue, Gross Margin and Market Share (2016-2017)
3 Global Gene Therapy for Age-related Macular Degeneration Market Competition, by Players
3.1 Global Gene Therapy for Age-related Macular Degeneration Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Gene Therapy for Age-related Macular Degeneration Players Market Share
3.2.2 Top 10 Gene Therapy for Age-related Macular Degeneration Players Market Share
3.3 Market Competition Trend
4 Global Gene Therapy for Age-related Macular Degeneration Market Size by Regions
4.1 Global Gene Therapy for Age-related Macular Degeneration Revenue and Market Share by Regions
4.2 North America Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
4.3 Europe Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
4.5 South America Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
5 North America Gene Therapy for Age-related Macular Degeneration Revenue by Countries
5.1 North America Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)
5.2 USA Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
5.3 Canada Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
5.4 Mexico Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
6 Europe Gene Therapy for Age-related Macular Degeneration Revenue by Countries
6.1 Europe Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)
6.2 Germany Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
6.3 UK Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
6.4 France Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
6.5 Russia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
6.6 Italy Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue by Countries
7.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)
7.2 China Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
7.3 Japan Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
7.4 Korea Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
7.5 India Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
8 South America Gene Therapy for Age-related Macular Degeneration Revenue by Countries
8.1 South America Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)
8.2 Brazil Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
8.3 Argentina Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
8.4 Colombia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Gene Therapy for Age-related Macular Degeneration by Countries
9.1 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue by Countries (2013-2018)
9.2 Saudi Arabia Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
9.3 UAE Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
9.4 Egypt Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
9.5 Nigeria Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
9.6 South Africa Gene Therapy for Age-related Macular Degeneration Revenue and Growth Rate (2013-2018)
10 Global Gene Therapy for Age-related Macular Degeneration Market Segment by Type
10.1 Global Gene Therapy for Age-related Macular Degeneration Revenue and Market Share by Type (2013-2018)
10.2 Global Gene Therapy for Age-related Macular Degeneration Market Forecast by Type (2018-2023)
10.3 Subretinal Revenue Growth Rate (2013-2023)
10.4 Intravitreal Revenue Growth Rate (2013-2023)
10.5 Unspecified Revenue Growth Rate (2013-2023)
11 Global Gene Therapy for Age-related Macular Degeneration Market Segment by Application
11.1 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2013-2018)
11.2 Gene Therapy for Age-related Macular Degeneration Market Forecast by Application (2018-2023)
11.3 Monotherapy Revenue Growth (2013-2018)
11.4 Combination Therapy Revenue Growth (2013-2018)
12 Global Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2018-2023)
12.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2018-2023)
12.2 Global Gene Therapy for Age-related Macular Degeneration Market Forecast by Regions (2018-2023)
12.3 North America Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
12.4 Europe Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
12.6 South America Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Gene Therapy for Age-related Macular Degeneration Picture
Table Product Specifications of Gene Therapy for Age-related Macular Degeneration
Table Global Gene Therapy
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
